Shuhong Li

State Key Laboratory Of Chemical Oncogenomics, Shenzhen Key Laboratory Of Chemical Genomics
Shenzhen, 518055, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational study.

Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational study.

Journal: Antibody therapeutics

Published: September 09, 2025

Novel Loop-Structure-Based CD19/CD22 Dual-Target CAR-T Therapy for High-Risk Diffuse Large B-Cell Lymphoma Presenting with Hemophagocytic Lymphohistiocytosis: A Case Report.

Novel Loop-Structure-Based CD19/CD22 Dual-Target CAR-T Therapy for High-Risk Diffuse Large B-Cell Lymphoma Presenting with Hemophagocytic Lymphohistiocytosis: A Case Report.

Journal: Cancer management and research

Published: February 24, 2025

Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors.

Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors.

Journal: Cell reports. Medicine

Published: February 19, 2025

BAFF-based trifunctional T-cell engagers trigger robust tumor immunity against B-cell malignancies.

BAFF-based trifunctional T-cell engagers trigger robust tumor immunity against B-cell malignancies.

Journal: Protein & cell

Published: February 04, 2025

Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies.

Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies.

Journal: Nature communications

Published: January 18, 2024

A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies.

A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies.

Journal: Protein & cell

Published: January 04, 2024

A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy.

A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy.

Journal: Theranostics

Published: May 12, 2022

A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL.

A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL.

Journal: Blood

Published: March 09, 2022

Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers.

Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers.

Journal: ACS synthetic biology

Published: April 15, 2021

A tumor-targeted immune checkpoint blocker.

A tumor-targeted immune checkpoint blocker.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 24, 2019

Showing 1-10 of 10

Last Updated: 09/26/2026